Ovarian cancer is the malignancy with the highest rate of death from tumors of the female reproductive system and the main treatment options are tumor reduction and post-surgical platinum-based chemotherapy. Unfortunately, some patients will develop platinum resistance after multiple recurrences. Given that ovarian cancer is a heterogeneous disease with complex molecular and genetic alterations, the identification of specific molecular targets will be of great benefit in gaining a deeper understanding of the mechanisms of ovarian cancer development and progression.
As research into targeted therapies continues, the treatment of ovarian cancer is gradually shifting from conventional chemotherapy to targeted therapies. Targeted drugs such as PARP inhibitors and anti-angiogenic drugs have become important modalities for the maintenance treatment of ovarian cancer. At the same time, targeted therapy also suffers from ineffective use, high rates of adverse reactions and high prices. With the development of next-generation sequencing technology, targeted therapeutic agents developed for specific molecules in ovarian cancer may provide a wider range of treatment options for ovarian cancer patients and offer new strategies for individualized treatment. Immunotherapy, as well as ferroptosis pathway modulation, has also provided new ideas for targeted therapy in ovarian cancer.
How to increase the efficacy and reduce the side effects of existing targeted drugs for ovarian cancer, as well as exploring the possibility of developing new targeted drugs, are issues that are urgently before us today. We’re eager to identify new targeted treatments for ovarian cancer and investigate biomarkers associated with the ovarian cancer targeted medication. We encourage computational or experimental research as well as pharmacological activity studies.
In this research topic, we welcome researchers to submit perspectives, original articles, reviews, comments, and letters on the topic. Including but not limited to the following topics:
1. Targeting ovarian cancer by novel molecules.
2. Influence of novel ovarian cancer therapeutics on targeted medication.
3. Big data analysis of ovarian cancer networks involved in metabolic, and inflammatory pathways.
4. Clinical translation strategies for ovarian cancer targeted therapeutics.
5. Non-coding RNA and targeted therapy for ovarian cancer.
6. Anti-angiogenic drugs and ovarian cancer targeted medication.
7. PARP inhibitors and ovarian cancer targeted medication.
8. Immunotherapy and targeted ovarian cancer treatment.
9. Mechanisms of drug resistance and targeted therapeutic strategies in ovarian cancer.
10. Ferroptosis and ovarian cancer targeted medication.
Ovarian cancer is the malignancy with the highest rate of death from tumors of the female reproductive system and the main treatment options are tumor reduction and post-surgical platinum-based chemotherapy. Unfortunately, some patients will develop platinum resistance after multiple recurrences. Given that ovarian cancer is a heterogeneous disease with complex molecular and genetic alterations, the identification of specific molecular targets will be of great benefit in gaining a deeper understanding of the mechanisms of ovarian cancer development and progression.
As research into targeted therapies continues, the treatment of ovarian cancer is gradually shifting from conventional chemotherapy to targeted therapies. Targeted drugs such as PARP inhibitors and anti-angiogenic drugs have become important modalities for the maintenance treatment of ovarian cancer. At the same time, targeted therapy also suffers from ineffective use, high rates of adverse reactions and high prices. With the development of next-generation sequencing technology, targeted therapeutic agents developed for specific molecules in ovarian cancer may provide a wider range of treatment options for ovarian cancer patients and offer new strategies for individualized treatment. Immunotherapy, as well as ferroptosis pathway modulation, has also provided new ideas for targeted therapy in ovarian cancer.
How to increase the efficacy and reduce the side effects of existing targeted drugs for ovarian cancer, as well as exploring the possibility of developing new targeted drugs, are issues that are urgently before us today. We’re eager to identify new targeted treatments for ovarian cancer and investigate biomarkers associated with the ovarian cancer targeted medication. We encourage computational or experimental research as well as pharmacological activity studies.
In this research topic, we welcome researchers to submit perspectives, original articles, reviews, comments, and letters on the topic. Including but not limited to the following topics:
1. Targeting ovarian cancer by novel molecules.
2. Influence of novel ovarian cancer therapeutics on targeted medication.
3. Big data analysis of ovarian cancer networks involved in metabolic, and inflammatory pathways.
4. Clinical translation strategies for ovarian cancer targeted therapeutics.
5. Non-coding RNA and targeted therapy for ovarian cancer.
6. Anti-angiogenic drugs and ovarian cancer targeted medication.
7. PARP inhibitors and ovarian cancer targeted medication.
8. Immunotherapy and targeted ovarian cancer treatment.
9. Mechanisms of drug resistance and targeted therapeutic strategies in ovarian cancer.
10. Ferroptosis and ovarian cancer targeted medication.
